Ipsen has entered into a definitive agreement to acquire Memo Therapeutics AG for an initial payment of €200 million. The deal centers on the acquisition of the antibody candidate potravitug, which is currently in Phase II clinical development for the treatment of BK virus (BKPyV) infection in kidney transplant recipients.
Why Ipsen is targeting BK virus infections
The acquisition aims to address the clinical complications associated with BK polyomavirus (BKPyV) in patients who have undergone renal transplantation. According to Ipsen, BK virus-associated nephropathy remains a significant clinical challenge. Potravitug is designed as a first-in-class therapy intended to neutralize the virus. Christelle Huguet, Executive Vice President and Head of Research and Development at Ipsen, stated that the asset offers an opportunity to expand the company’s rare disease portfolio by addressing the clinical consequences of BK virus-associated nephropathy in kidney transplant recipients.
Financial terms of the acquisition
Ipsen will pay €200 million to Memo Therapeutics shareholders at the closing of the transaction, which is expected to occur in the third quarter of 2026. The agreement is structured on a cash-free, debt-free basis. Beyond the initial upfront payment, the deal includes potential additional payments contingent upon the achievement of development, regulatory, and commercial milestones. These deferred payments could exceed €700 million.
What happens next for Potravitug
Following the close of the transaction, Ipsen will assume control of the development program for potravitug. The antibody has already reached the Phase II clinical stage.
Key takeaways
- Transaction Value: Ipsen will pay an initial €200 million, with potential earn-outs exceeding €700 million based on future milestones.
- Primary Asset: The acquisition grants Ipsen full rights to potravitug, a Phase II antibody.
- Target Indication: The therapy is intended for kidney transplant recipients suffering from BK polyomavirus.
- Timeline: The companies anticipate closing the transaction during the third quarter of 2026.
This acquisition aligns with Ipsen’s broader corporate strategy of targeting rare disease assets to bolster its R&D pipeline.